Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4B | O94953 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490735 | 0.78 | PARP1 (0.46) | PARP1KEAP1NFE2L2SYKCHEK2 | |
| SCHEMBL31676657 | 0.78 | PARP1 (0.46) | PARP1KEAP1NFE2L2SYKCHEK2 | |
| SCHEMBL21381429 | 0.77 | JAK2 (0.41) | PARP1KEAP1NFE2L2AURKARPS6KB1 | |
| SCHEMBL1724612 | 0.73 | PARP1 (0.48) | PARP1KEAP1NFE2L2SYKCHEK2 | |
| SCHEMBL27559308 | 0.72 | BCAT2 (0.53) | PARP1KEAP1NFE2L2SYKCHEK2 | |
| SCHEMBL4410159 | 0.72 | BCAT2 (0.49) | PARP1KEAP1NFE2L2IRAK4 | |
| SCHEMBL30042190 | 0.72 | BCAT2 (0.53) | PARP1KEAP1NFE2L2SYKCHEK2 | |
| SCHEMBL251450 | 0.72 | PARP1 (0.45) | PARP1KEAP1NFE2L2SYKCHEK2 | |
| SCHEMBL28770413 | 0.71 | KEAP1 (0.42) | PARP1KEAP1NFE2L2AURKAIRAK4 | |
| SCHEMBL27704990 | 0.70 | KEAP1 (0.57) | PARP1KEAP1NFE2L2IRAK4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-11505547-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2022-11-22 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3717465-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | PARP1 1584/4885KEAP1 276/4885NFE2L2 180/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | PARP1 1584/4885KEAP1 276/4885NFE2L2 180/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | PARP1 1430/4885KEAP1 333/4885NFE2L2 186/4885 |
| US-11505547-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | PARP1 1584/4885KEAP1 276/4885NFE2L2 180/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | PARP1 1584/4885KEAP1 276/4885NFE2L2 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.